ARTICLE | Clinical News

UC Davis delays KaloBios trial on Shkreli news

December 22, 2015 1:49 AM UTC

University of California Davis postponed the start of a Phase I trial of lenzilumab ( KB003) from KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) to treat chronic myelomonocytic leukemia (CMML). In a statement, the university said it would suspend the activation of the trial "in light of the arrest of KaloBios CEO Martin Shkreli," and that the suspension "will remain in effect pending further analysis."

UC Davis declined to comment on why Shkreli's arrest has any relationship to clinical trial starts. ...